Myeloma

Top Story

FDA grants fast track designation to selinexor for relapsed or refractory diffuse large B-cell lymphoma

November 11, 2018
In the Journals Plus

Elotuzumab combination extends PFS for certain patients with relapsed, refractory multiple myeloma

November 7, 2018
The addition of the elotuzumab to pomalidomide and dexamethasone conferred a significant PFS benefit among certain patients with relapsed or refractory multiple myeloma…
FDA News

FDA approves triplet regimen for relapsed, refractory myeloma

November 6, 2018
The FDA approved elotuzumab plus pomalidomide and dexamethasone for treatment of adults with relapsed or refractory multiple myeloma. The triplet regimen of elotuzumab…

Frontline daratumumab regimen extends PFS in multiple myeloma

October 30, 2018
A randomized phase 3 trial to evaluate the addition of daratumumab to lenalidomide and dexamethasone for the frontline treatment of patients with multiple myeloma met…
More Headlines »
CME CNE CPE

Exploring New Immune Checkpoint Inhibitor Paradigms in Advanced Melanoma

This activity is supported by an educational grant from Bristol-Myers Squibb.

The integration of immune checkpoint inhibitors into treatment algorithms for the management of advanced genitourinary…
More »
Video
Meeting News

VIDEO: Visiting expert program helps community providers learn about immuno-oncology

June 12, 2017
More »
Resource Centers
At Issue: Multiple Myeloma Resource Center

At Issue: Multiple Myeloma Resource Center

CME CPE CNE

Decisions, Decisions: Differentiating Checkpoint Inhibitors for Bladder Cancer

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

Lung cancer is a leading cause of cancer death worldwide. The American Cancer Society estimates that there will be…
More »